Nicholas G. Galakatos is an entrepreneur and businessperson who founded TransForm Pharmaceuticals, Inc., Clarus Ventures LLC and Millennium Predictive Medicine, Inc. and who has been at the helm of 5 different companies. Currently, Dr. Galakatos holds the position of Chairman of Anthos Therapeutics, Inc. and Chairman & Chief Executive Officer of TransForm Pharmaceuticals, Inc.
He is also General Partner for MPM Asset Management II LLC, Global Head-Life Sciences at The Blackstone Group, Inc. and Member-Director Council at David H. Koch Institute for Integrative Cancer Research and on the board of 5 other companies.
Nicholas G. Galakatos previously held the position of Vice President at Venrock Associates, General Partner for MPM Capital Inc and General Partner for MPM BioVentures III GP LP (a subsidiary of MPM Capital Inc), Chairman for Hypnion, Inc., Independent Director at Entasis Therapeutics Holdings, Inc., Vice President-New Businesses at Millennium Pharmaceuticals, Inc., Head-Molecular Biology Research at Novartis Corp., Principal at Novartis Pharmaceuticals Corp. and Managing Director at Clarus Ventures LLC.
Nicholas G. Galakatos received a doctorate from Massachusetts Institute of Technology and an undergraduate degree from Reed College.